CIBC Asset Management Inc Has $10.51 Million Holdings in DexCom, Inc. $DXCM

CIBC Asset Management Inc grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 29.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 156,185 shares of the medical device company’s stock after acquiring an additional 35,824 shares during the quarter. CIBC Asset Management Inc’s holdings in DexCom were worth $10,510,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Andra AP fonden bought a new stake in DexCom in the 2nd quarter valued at $26,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of DexCom during the 2nd quarter worth about $26,000. SJS Investment Consulting Inc. raised its position in shares of DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares during the last quarter. Financial Consulate Inc. acquired a new position in shares of DexCom during the third quarter valued at about $29,000. Finally, Sound Income Strategies LLC lifted its stake in shares of DexCom by 83.8% in the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock valued at $43,000 after buying an additional 285 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on DXCM shares. Leerink Partners reaffirmed an “outperform” rating and issued a $92.00 price target on shares of DexCom in a report on Tuesday, December 16th. Stifel Nicolaus began coverage on DexCom in a research note on Tuesday, October 21st. They issued a “buy” rating and a $85.00 target price for the company. Canaccord Genuity Group set a $99.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Piper Sandler set a $75.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Friday, October 31st. Finally, Morgan Stanley restated an “overweight” rating on shares of DexCom in a research note on Monday, January 12th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.30.

DexCom Stock Up 0.7%

DXCM opened at $73.34 on Tuesday. The firm has a market cap of $28.60 billion, a price-to-earnings ratio of 40.74, a PEG ratio of 1.31 and a beta of 1.48. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The firm’s 50-day simple moving average is $66.71 and its 200-day simple moving average is $70.98. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $93.25.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.45 earnings per share. Equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, COO Jacob Steven Leach acquired 18,200 shares of DexCom stock in a transaction on Monday, November 10th. The shares were bought at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the purchase, the chief operating officer owned 331,697 shares in the company, valued at $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Richard Alexander Collins sold 3,948 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $55.17, for a total value of $217,811.16. Following the sale, the director owned 37,994 shares in the company, valued at $2,096,128.98. The trade was a 9.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 7,866 shares of company stock valued at $448,177 in the last three months. 0.32% of the stock is owned by corporate insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.